Pacira BioSciences, Inc. (PCRX)
NASDAQ: PCRX · IEX Real-Time Price · USD
19.37
-0.85 (-4.20%)
At close: Jul 19, 2024, 4:00 PM
19.38
+0.01 (0.05%)
Pre-market: Jul 20, 2024, 9:29 AM EDT
Pacira BioSciences Stock Forecast
Stock Price Forecast
The 10 analysts with 12-month price forecasts for Pacira BioSciences stock have an average target of 46.1, with a low estimate of 25 and a high estimate of 57. The average target predicts an increase of 138.00% from the current stock price of 19.37.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for PCRX stock from 10 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 | Jul '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 6 | 7 | 7 | 7 | 7 | 6 |
| Hold | 0 | 0 | 0 | 0 | 0 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 10 | 10 | 10 | 10 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Piper Sandler | Piper Sandler | Buy Maintains $42 | Buy | Maintains | $42 | +116.83% | Jul 3, 2024 |
| Barclays | Barclays | Buy → Hold Downgrades $38 → $25 | Buy → Hold | Downgrades | $38 → $25 | +29.07% | Jul 3, 2024 |
| Needham | Needham | Strong Buy Reiterates $43 | Strong Buy | Reiterates | $43 | +121.99% | Jul 2, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $57 | Strong Buy | Reiterates | $57 | +194.27% | Jul 2, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $57 | Strong Buy | Reiterates | $57 | +194.27% | May 8, 2024 |
Financial Forecast
Revenue This Year
707.20M
from 674.98M
Increased by 4.77%
Revenue Next Year
775.06M
from 707.20M
Increased by 9.60%
EPS This Year
2.83
from 0.89
Increased by 217.84%
EPS Next Year
3.66
from 2.83
Increased by 29.25%
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 732.7M | 819.2M | 929.5M | 1.0B | 1.3B |
| Avg | 707.2M | 775.1M | 849.7M | 900.5M | 1.0B |
| Low | 665.0M | 721.3M | 746.1M | 793.9M | 889.0M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 8.5% | 15.8% | 19.9% | 19.9% | 44.5% |
| Avg | 4.8% | 9.6% | 9.6% | 6.0% | 16.4% |
| Low | -1.5% | 2.0% | -3.7% | -6.6% | -1.3% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 3.38 | 4.50 | 5.89 | 7.02 | 8.02 |
| Avg | 2.83 | 3.66 | 4.40 | 5.07 | 5.95 |
| Low | 2.19 | 2.69 | 2.65 | 3.22 | 4.00 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 279.9% | 59.2% | 61.1% | 59.7% | 58.3% |
| Avg | 217.8% | 29.2% | 20.3% | 15.2% | 17.4% |
| Low | 145.6% | -5.1% | -27.6% | -26.7% | -21.1% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.